JP2023528713A - Ｇｐｒ４０アゴニスト - Google Patents

Ｇｐｒ４０アゴニスト Download PDF

Info

Publication number
JP2023528713A
JP2023528713A JP2022551555A JP2022551555A JP2023528713A JP 2023528713 A JP2023528713 A JP 2023528713A JP 2022551555 A JP2022551555 A JP 2022551555A JP 2022551555 A JP2022551555 A JP 2022551555A JP 2023528713 A JP2023528713 A JP 2023528713A
Authority
JP
Japan
Prior art keywords
alkyl
pharmaceutically acceptable
solvate
acceptable salt
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022551555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023528713A5 (https=
Inventor
セブハト，イヤス
ホウ，シューウェン
マチュー，サイモン
Original Assignee
キャリーオペ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by キャリーオペ，インク． filed Critical キャリーオペ，インク．
Publication of JP2023528713A publication Critical patent/JP2023528713A/ja
Publication of JP2023528713A5 publication Critical patent/JP2023528713A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/306—Arylalkanephosphinic acids, e.g. Ar-(CH2)n-P(=X)(R)(XH), (X = O,S, Se; n>=1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyridine Compounds (AREA)
JP2022551555A 2020-02-28 2021-02-26 Ｇｐｒ４０アゴニスト Pending JP2023528713A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202062983438P 2020-02-28 2020-02-28
US62/983,438 2020-02-28
US202063076113P 2020-09-09 2020-09-09
US63/076,113 2020-09-09
US202063117074P 2020-11-23 2020-11-23
US63/117,074 2020-11-23
US202163147982P 2021-02-10 2021-02-10
US63/147,982 2021-02-10
PCT/US2021/019973 WO2021174046A1 (en) 2020-02-28 2021-02-26 Gpr40 agonists

Publications (2)

Publication Number Publication Date
JP2023528713A true JP2023528713A (ja) 2023-07-06
JP2023528713A5 JP2023528713A5 (https=) 2024-02-21

Family

ID=77490353

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022551555A Pending JP2023528713A (ja) 2020-02-28 2021-02-26 Ｇｐｒ４０アゴニスト

Country Status (9)

Country Link
US (1) US20230151037A1 (https=)
EP (1) EP4110760A4 (https=)
JP (1) JP2023528713A (https=)
CN (1) CN115867536A (https=)
AU (1) AU2021225966A1 (https=)
CA (1) CA3173732A1 (https=)
TW (1) TW202140424A (https=)
UY (1) UY39106A (https=)
WO (1) WO2021174046A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220150270A (ko) 2019-10-07 2022-11-10 칼리오페, 인크. Gpr119 효능제
TW202140440A (zh) 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
EP4337202A4 (en) 2021-06-18 2025-04-02 Aligos Therapeutics, Inc. METHODS AND COMPOSITIONS FOR TARGETING PD-L1
EP4448512A4 (en) 2021-12-16 2025-11-19 Aligos Therapeutics Inc METHODS AND COMPOSITIONS FOR TARGETING PD-L1
CN118724767A (zh) * 2023-03-28 2024-10-01 南京华狮新材料有限公司 一种氨基酸衍生物及其制备方法和作为中间体合成l-草铵膦的方法
CN116178281B (zh) * 2023-04-27 2023-07-21 中国药科大学 一种双功能免疫抑制剂及其制备方法和应用
WO2025136929A1 (en) * 2023-12-19 2025-06-26 Kallyope, Inc. Gpr40 agonists
WO2025137310A1 (en) * 2023-12-22 2025-06-26 Kallyope, Inc. Crystalline gpr40 agonist and methods of making
WO2026019701A1 (en) * 2024-07-15 2026-01-22 Venenum Biodesign, LLC Substituted phenylsulfonamides as mgat2 inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP2007525516A (ja) * 2004-02-27 2007-09-06 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
WO2013122028A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
JP2013533283A (ja) * 2010-07-23 2013-08-22 コネクシオス ライフ サイエンシズ プライベート リミテッド Ｇｐｒ４０のアゴニスト
WO2015084692A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US20160009662A1 (en) * 2014-07-09 2016-01-14 Janssen Pharmaceutica Nv Pyrazine gpr40 agonists for the treatment of type ii diabetes
US20160332968A1 (en) * 2014-02-06 2016-11-17 Harry CHOBANIAN Antidiabetic compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8119617B2 (en) * 2006-08-23 2012-02-21 Novartis Ag aSMase inhibitors
US20220226298A1 (en) * 2019-05-29 2022-07-21 Kallyope, Inc. Gpr40 agonists

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007525516A (ja) * 2004-02-27 2007-09-06 アムジエン・インコーポレーテツド 代謝疾患の治療に使用するための、化合物、薬学的組成物及び方法
WO2005087710A1 (ja) * 2004-03-15 2005-09-22 Takeda Pharmaceutical Company Limited アミノフェニルプロパン酸誘導体
JP2013533283A (ja) * 2010-07-23 2013-08-22 コネクシオス ライフ サイエンシズ プライベート リミテッド Ｇｐｒ４０のアゴニスト
WO2013122028A1 (ja) * 2012-02-13 2013-08-22 武田薬品工業株式会社 芳香環化合物
WO2015084692A1 (en) * 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US20160332968A1 (en) * 2014-02-06 2016-11-17 Harry CHOBANIAN Antidiabetic compounds
US20160009662A1 (en) * 2014-07-09 2016-01-14 Janssen Pharmaceutica Nv Pyrazine gpr40 agonists for the treatment of type ii diabetes

Also Published As

Publication number Publication date
WO2021174046A1 (en) 2021-09-02
AU2021225966A1 (en) 2022-09-15
TW202140424A (zh) 2021-11-01
CN115867536A (zh) 2023-03-28
EP4110760A4 (en) 2024-09-18
EP4110760A1 (en) 2023-01-04
US20230151037A1 (en) 2023-05-18
CA3173732A1 (en) 2021-09-02
UY39106A (es) 2021-09-30

Similar Documents

Publication Publication Date Title
JP7745559B2 (ja) Ｇｐｒ４０アゴニスト
JP2023528713A (ja) Ｇｐｒ４０アゴニスト
CN114945560B (zh) Gpr119激动剂
EP3976576A1 (en) Gpr40 agonists
EP4069708A1 (en) Sstr5 antagonists
AU2021275038A1 (en) AMPK activators
HK40085449A (en) Gpr40 agonists
TW202340185A (zh) Ampk活化劑
WO2025136929A1 (en) Gpr40 agonists
HK40085450A (en) Gpr40 agonists
CN121889394A (zh) 作为pkmyt1抑制剂的新型化合物及其用途

Legal Events

Date Code Title Description
RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240213

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20250130

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250213

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250804